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GMC’s proposals for revalidation would not be accurate,
economical, or fair
Editor—To anyone involved in assessing
medical competence, the General Medical
Council’s proposal for revalidation is
potentially unfair and inaccurate, and very
expensive.1
The proposal has two parts. The
first—annual appraisal—is uncontroversial; it
can be helpful.2 The second is a summative
assessment every five years, aggregating the
appraisals, which is reviewed by two doctors
from the appraisee’s field and a lay person;
collectively they determine whether to
recommend revalidation. This does not lead
to de›registration: it acts as a sieve, seeking to
identify potentially inadequate doctors, who
would then undergo further assessment
under the performance procedures devised
by Southgate et al.3 It is the sieve that is
inappropriate.
One difficulty in assessment is making it
fair between candidates. In examinations,
this requires minimisation of inter›
examinee variables—for example, the same
assessors judge the same attributes of all
candidates—and thorough training of asses›
sors. The General Medical Council pro›
poses an individual group of assessors for
each doctor’s review. The levels of judgment
of the assessors will differ considerably, each
group being different. Serious training for
all assessors for the thousands of candidates
assessed annually (extraordinarily, the
council cannot indicate numbers) seems
improbable: an assessment of osteopaths’
portfolios required up to three days’
training for assessors (B Jolly, personal
communication).
Portfolio assessment has good face
validity and may be useful when used
formatively.2 Few evaluations have been con›
ducted of it; research in the medical field
suggests that it is subject to assessor bias and
is unreliable and inaccurate.4
Estimates of the time needed for the
review (involving three assessors examining
five›year portfolios and interviewing the
appraisee; say five days for each professional
to consider the submission, interview, and
report and five days’ preparation for the
appraisee) suggest a cost of at least £50m a
year, or an opportunity cost of around 1% of
clinicians’ time. This is an enormous
expense to identify, inaccurately, those
doctors to subject to further assessment.
Peer associate ratings, used in the United
States,5 could be quicker and more accurate
but might be inappropriate for some groups
—for example, singlehanded general practi›
tioners. But one could readily devise a paper
based assessment exercise of a maximum
one day’s duration as a sieve towards the
performance procedures. Though not
directly assessing performance, it would tap
measures of clinical competence best pre›
dicting clinical performance, assessing ethi›
cal and communication issues, as well as
knowledge and problem solving. It would
allow the appraisals to remain formative.
And it would be accurate, economical of
time and money, and fair.
Anyone for testing?
Richard Wakeford convenor of Cambridge
conferences on medical education
Hughes Hall, Cambridge CB1 2EW
rew5@admin.cam.ac.uk
1 General Medical Council. Revalidation. Available at:
www.gmc›uk.org/revalidation/pdffrm.html (accessed 2
November 2000).
2 Mathers NJ, Challis MC, Howe AC, Field NJ. Portfolios in
continuing medical education—effective and efficient? Med
Educ 1999;33:521›30.
3 Southgate L, Pringle M. Revalidation in the United
Kingdom: general principles based on experience in gen›
eral practice. BMJ 1999;319:1180›3.
4 Pitts J, Coles C, Thomas P. Educational portfolios in the
assessment of general practice trainers: reliability of asses›
sors. Med Educ 1999;33:515›20.
5 Ramsey PG, Weinrich MD, Carline JD, Inui TS, Larson EB,
LoGerfo JP. Use of peer ratings to evaluate physician per›
formance. JAMA 1993;269:1655›60.
BMA approves acupuncture
BMA report is wrong
Editor—The BMA report on acupuncture
is regrettable. It suggests, among other
things, that acupuncture is effective for back
pain, dental pain, and migraine. Three
recent systematic reviews show the
importance of basing judgments on high
quality information.
For back pain, four randomised and
blind studies showed no benefit; five open
studies showed benefit.1 The BMA’s conclu›
sion that acupuncture was effective in back
pain was based on all nine studies.
For dental pain, a review of 16 studies
concluded that it was effective.2 Many of
these were not randomised, were not blind,
or had major flaws. Only three small studies
were adequate, and these showed no
convincing benefit.3
For migraine, trials showing a significant
benefit from acupuncture were inadequately
randomised or not blind.4 The reviewers
themselves were highly circumspect about
ascribing any clinical significance to acu›
puncture.
The BMA report concluded that results
for acupuncture are inconclusive in other
conditions. These are weasel words. For
smoking cessation the 12 month cessation
rate with acupuncture was 14% (95%
confidence interval 11% to 17%), which was
no different from the placebo response with
nicotine gum of 12% (11% to 13%).
Trials of acupuncture suffer problems of
poor quality, which leads to bias. Reviews
with poor quality studies overestimate treat›
ment effects. Original reports may come to
the wrong conclusion from their own data, a
fact true of two of 13 studies of acupuncture
in neck and back pain.5
For those areas where the BMA report
thought there was evidence of effectiveness
of acupuncture, either there was none or
what quality evidence there was indicated
lack of effectiveness. For those areas where
the BMA thought the results inconclusive,
there was either no useful information or
acupuncture was shown to be ineffective.
Doctors should beware. There is no use›
ful evidence showing that acupuncture
helps; there is evidence that it harms.
Perhaps the important point is that we
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should not deceive ourselves, or people who
trust our recommendations. There is no
gold standard evidence that acupuncture
improves pain or anything else. The BMA
report is quite simply wrong.
R A Moore consultant
biochemistandrew.moore@pru.ox.ac.uk
H J McQuay professor of pain relief
A D Oldman research associate
L E Smith research associate
Pain Research and Nuffield Department of
Anaesthetics, University of Oxford, The Churchill,
Oxford OX3 7LJ
1 Ernst E, White AR. Acupuncture for back pain: a
meta›analysis of randomized controlled trials. Arch Intern
Med 1998;158:2235›41.
2 Ernst E, Pittler MH. The effectiveness of acupuncture in
treating acute dental pain. Br Dent J 1998;184:443›7.
3 Smith LA, Oldman AD. Acupuncture and dental pain. Br
Dent J 1999;186:158›9.
4 Melchart D, Linde K, Fischer P, White A, Allais G, Vickers
A, et al. Acupuncture for recurrent headaches: a systematic
review of randomized controlled trials. Cephalalgia
1999;19:779›86.
5 Smith LA, Oldman AD, McQuay HJ, Moore RA. Teasing
apart quality and validity in systematic reviews: an example
from acupuncture trials in chronic neck and back pain.
Pain 2000;86:119›32.
Is approval of acupuncture for back pain
really evidence based?
Editor—The BMA has concluded that acu›
puncture should be made more widely avail›
able to British people through the NHS and
that general practitioners should receive
training in it.1 The association seems to base
its conclusion on three things: evidence
showing that “acupuncture is more effective
than control interventions for back pain,
nausea and vomiting, migraine and dental
pain"; the fact that 47% of general
practitioners have arranged for their
patients to receive acupuncture; and the
wish of 46% of those professionals to receive
training in acupuncture in order to treat
their patients.2
The evidence on the effectiveness of
acupuncture in the treatment of back pain
seems to have been misinterpreted. The
Cochrane Collaboration Back Review
Group has published a major systematic
review of the effectiveness of acupuncture in
low back pain.3 This review followed a rigor›
ous methodology and an exhaustive search
for information. Its results indicated poor
research methods and contradictory results
from studies of acupuncture in low back
pain. The review was therefore inconclusive
and could not serve as a basis for
recommending acupuncture. This was con›
sistent with the results of past systematic
reviews4 and with a randomised trial that
compared the effectiveness of acupuncture
with that of massage and self care education
(D C Cherkin et al, fourth international
forum for primary care research on low
back pain, Eilat, Israel, 2000).
Although scientific evidence in this
respect has not changed much in several
years, public and medical opinion does
seem to have changed. The establishment of
a double standard for the approval of a
treatment technique, bowing to the
pressure of public opinion and not taking
into account evidence based recommenda›
tions, is harmful to the public’s health and
to the economy of the NHS. In time it could
also be harmful to the treatment approved
with the lower standard and to the credi›
bility of its practitioners and the institutions
that recommend it.
Clinical practice is not always based on
scientific evidence and the search for an effi›
cient use of resources. Many years ago
patients were convinced of the effectiveness
of leeches for the treatment of infectious
diseases, doctors prescribed them, and
apothecaries sold them. Nevertheless,
despite public demand and medical interest,
evidence of the efficacy, safety, and cost
effectiveness of the treatment was lacking.
This lesson from the past should be kept in
mind.
Francisco M Kovacs president
María Teresa Gil del Real coordinator
Kovacs Foundation, Scientific Department,
Palma de Mallorca 07012, Spain
mtgildelreal@kovaks.org
The authors are members of the management com›
mittee of the COST B4 programme on unconven›
tional medicine.
1 Silvert M. Acupuncture wins BMA approval. BMJ 2000;
321:11. (1 July.)
2 BMA. Acupuncture: efficacy, safety, and practice. London: BMA,
2000.
3 Van Tulder MW, Cherkin DC, Berman B, Lao L, Koes BW.
The effectiveness of acupuncture in the management of
acute and chronic low back pain. A systematic review
within the framework of the Cochrane Collaboration Back
Review Group. Spine 1999;24:1113›23.
4 Ter Riet G, Kleijnen J, Knipschild P. Acupuncture and
chronic pain: a criteria›based meta›analysis. J Clin
Epidemiol 1990;43:1191›9.
Lung cancer and passive
smoking
Turning over the wrong stone
Editor—In their reanalysis of the epidemio›
logical evidence on lung cancer and
smoking Copas and Shi1 assert that after
allowing for publication bias the apparent
average excess risk of lung cancer from pas›
sive smoking2 would drop from 24% to 15%.
Despite the lack of supporting data,3 we are
asked to believe solely on the basis of statisti›
cal inference that such data must be hiding
under a stone. They are, however, turning
over the wrong stone.
More important than publication bias is
the underestimation of risk that occurs
when these studies assess exposure solely on
the basis of whether non›smokers either
lived or did not live with a smoker,2 when
other exposure exists.
Where other exposure is common—for
example, in childhood, in social situations,
or in the workplace—the risk of lung cancer
may be seriously underestimated. Spouses
of non›smokers exposed in other circum›
stances will be misclassified as non›exposed,
contaminating the referent group, and
attenuating the risk estimate. For example,
Hackshaw et al estimate that the odds ratio
would have been 1.42 (95% confidence
interval 1.21 to 1.66) if those with spousal
exposure alone were compared with those
who were truly unexposed.2 By comparison,
in a recent meta›analysis of risk associated
with workplace exposure, Wells found an
estimated relative risk of 1.39 (1.15 to 1.68)
for the five studies meeting basic study qual›
ity standards.4 Repace and Lowrey found
that when both workplace exposure and an
unexposed referent group were taken into
account in the American Cancer Society
study of passive smoking and lung cancer, a
population relative risk of 1.2 increased to
1.7.5
Repace and Lowrey modelled the risk of
workplace exposure, estimating the average
relative risk at 2.0 for office workers in the
United States in the 1980s. This result is
consistent with a value reported by Rey›
nolds et al for women with 30 or more years
of workplace exposure—namely, at ages at
which lung cancer mortality begins to
become significant.5
Moreover, all of these analyses focus on
average risk. Repace et al estimated that
individuals at the 95th centile—for example,
those experiencing high smoker density and
low air exchange—have an exposure, and a
risk, as much as four times as high as those at
the median. This result is commensurate
with observations of dose5 and risk.2
Turning over stones may indeed alter
the estimated risk, but turning over the
right stone indicates that in the original
meta›analysis, the actual passive smoking›
lung cancer risk is underestimated, not
overestimated.
Kenneth C Johnson senior epidemiologist
Environmental Risk Assessment and Case
Surveillance Division, Cancer Bureau, Laboratory
Centre for Disease Control Health Protection
Branch Health Canada, Ottawa, Ontario, Canada
K1A 0L2
Ken_LCDC_Johnson@hc›sc.gc.ca
James Repace health physicist
Repace Associates, Secondhand Smoke
Consultants, Bowie, MD 20720, USA
repace@erols.com
Competing interests: None declared.
1 Copas JB, Shi JQ. Reanalysis of epidemiological evidence
of lung cancer and passive smoking. BMJ 2000; 320:417›8.
(12 February.)
2 Hackshaw AK, Law MR, Wald NJ. The accumulated
evidence on lung cancer and environmental tobacco
smoke. BMJ 1997;315:980›8.
3 Bero LA, Glantz SA, Rennie D. Publication bias and public
health policy on environmental tobacco smoke. JAMA
1994;272:133›6.
4 Wells AJ. Lung cancer and passive smoking at work. Am J
Public Health 1998;88:1025›9.
5 Repace JL, Jinot J, Bayard S, Emmons K, Hammond SK.
Air nicotine and saliva cotinine as indicators of passive
smoking exposure and risk. Risk Analysis 1998;18:71›83.
Increased risk is not disputed
Editor—In their paper on lung cancer and
passive smoking,1 Copas and Shi say that in
our review of passive smoking and lung can›
cer there is clear evidence of publication bias
and that allowing for this substantially
lowers the estimate of relative risk (which we
reported as 1.24 before correction for other
biases and confounding and 1.26 after
correction).2 Neither is correct.
It is proposed that large studies will tend
to be published regardless of their result but
small studies published only if they are posi›
tive (publication bias). As Copas and Shi
point out, studies with a large standard error
(indicating a small study) tend to be
Letters
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associated with a large relative risk (correla›
tion coefficient 0.35, P = 0.03), implying that
there may be some unpublished small nega›
tive studies. An indication of the size of the
effect can be obtained by restricting the
analysis to those studies with smaller
standard errors which are less susceptible to
increase publication bias. If the six studies
with the largest standard errors ( > 0.5) are
excluded there is no evidence for an associ›
ation between standard error and relative
risk (correlation coefficient 0.13, P = 0.48)
and the estimate of risk is 1.22; even if the 12
studies with the largest standard errors
( > 0.4) are excluded the estimate is 1.23;
neither is materially different from the
estimate based on all 37 studies (1.24). This
indicates that the effect of unpublished stud›
ies is likely to be negligible.
There is further evidence against mate›
rial publication bias in that 32 of the 39
studies reported non›significant results and
in 16 (41%) the authors had either
concluded that there was no effect (13) or
that the evidence was inconclusive (3),
suggesting that the passive smoking litera›
ture is one with a strong tendency for
positive results to be published while
negative results remain unpublished.
Even if one accepts the calculations of
Copas and Shi, their relative risk estimate,
which assumes that as many as 20% of all
studies are unpublished, is 1.15, not substan›
tially different from our own estimate (1.26)
and well within the confidence interval on
our result (1.06 to 1.47).2 Even under the
extreme assumption that 40% of studies
were not published their estimate (1.11)
would still be consistent with ours. Copas
and Shi do not dispute that there is an
increased risk of lung cancer due to passive
smoking nor do they seriously challenge our





Wolfson Institute of Preventive Medicine,
Department of Environmental and Preventive
Medicine, London EC1M 6BQ
Competing interests: None declared.
1 Copas JB, Shi JQ. Reanalysis of epidemiological evidence
of lung cancer and passive smoking. BMJ 2000; 320:417›8.
(12 February.)
2 Hackshaw AK, Law MR, Wald NJ. The accumulated
evidence on lung cancer and environmental smoke. BMJ
1997;315:980›8.
Nothing new was said
Editor—My reaction to this paper is a big
yawn. Copas and Shi think that there is evi›
dence of publication bias against small stud›
ies that reach the negative conclusion that
second hand smoke causes lung cancer. This
is nothing new, nor is the analysis they
present (based on something called a funnel
plot).1
Copas and Shi agree that a meta›
analysis of the published studies on passive
smoking and lung cancer shows a significant
increase in risk of 1.24. They compute that if
only 60% of the studies that have ever been
done were published and that the remaining
40% of studies that were done but never
published—and that no one has ever heard
of—were all negative, then the increase in
risk would only be 1.11 and not significant.
There is no evidence that these studies
were ever done. Our investigation suggests
that there is no publication bias.2
Copas and Shi also point out that if only
70% of the studies were published, and all
the unpublished studies showed no eleva›
tion in risk, then the pooled risk would be
1.13 and significant (P = .052).
So, you could argue that they proved
that, while failure to publish negative studies
would lower the true risk of lung cancer
associated with passive smoking, under any
reasonable guess at how much “unpub›
lished” research there was, there would still
be an increase in risk. But despite the fact
that many people have tried to find these
unpublished studies, no one has been able
to find them. The tobacco industry would
make sure we knew about them.
What Copas and Shi say is that if several
people did studies that found no effect of
passive smoking and lung cancer and found
no increase in risk, and we suddenly knew
about these papers, then our estimate of
how much the risk was increased would be
smaller. But the risk would still be increased.
The real killer from second hand smoke
is heart disease, not lung cancer. Heart
disease kills about 10 times more people than
lung cancer. Not even the tobacco industry
has contested the evidence on asthma.
So . . . what’s the big deal?
Stanton A Glantz professor of medicine
University of California, San Francisco,
CA 94143›0130, USA
glantz@medicine.ucsf.edu
Competing interests: None declared.
1 Copas JB, Shi JQ. Reanalysis of epidemiological evidence
of lung cancer and passive smoking. BMJ 2000; 320:417›8.
(12 February.)
2 Bero LA, Glantz SA, Rennie D. Publication bias and public
health policy on environmental tobacco smoke. JAMA
1994;272:133›6.
Scales for visual test of publication bias
are unfair
Editor—Funnel plots can be useful to detect
publication and related bias. The funnel plot
in the review of the epidemiological studies of
passive smoking and lung cancer by Copas
and Shi is, however, biased.1 In the absence of
publication bias the plot can be assumed to
be symmetrical only if relative risks are
plotted on a logarithmic scale. The scale used
by Copas and Shi is not logarithmic and will
give the visual impression of publication bias
even when there is none. Studies indicating
that exposure to passive smoking increases
the risk of lung cancer will spread out on the
graph because the relative risk may range
from 1.0 to infinity; in contrast studies
showing a reduction in risk will be com›
pressed in the range of 1.0 to zero. Visual
interpretation of the data is therefore not
possible by using the scale presented.
Christopher Cates general practitioner
Manor View Practice, Bushey Health Centre,
Bushey WD2 2NN
chriscates@email.msn.com
Competing interests: None declared.
1 Copas JB, Shi JQ. Reanalysis of epidemiological evidence
of lung cancer and passive smoking. BMJ 2000; 320:417›8.
(12 February.)
Authors’ reply
Editor—We thank the respondents for their
comments on our paper. We agree with
Johnson and Repace that the truth will be
hiding under stones. Some of these stones
(causes of bias) were considered in the
earlier review by Hackshaw et al1 They found
that some stones give an increase in risk,
others a decrease, and that on aggregate
they tend to cancel out. What we have done
is to add one more stone (publication bias)
and use it to redo their calculation of the
overall risk. It is not the wrong stone, just
one of several stones.
Johnson and Repace start their letter by
asserting that we claim that the excess risk
decreases from 24% to 15%. We have not
come up with a single best estimate. This is
impossible without making assumptions
that cannot be proved about how many
unpublished studies there are. Our conclu›
sion is that at least some publication bias is
needed to explain the trend in the funnel
plot, and that allowing for even a small
amount of study selection can give a
substantially lower figure.
The paper by Bero et al, which we did
refer to in our paper, suggests that there is
no publication bias.2 We would emphasise
the word “suggest"—neither their arguments
nor the fact that no unpublished papers
have been found mean that none exists. Our
analysis does not dispute that the risk is
increased; the question is by how much. Nei›
ther do we claim that the unpublished
papers were all negative. We can say nothing
at all about them, just that there may be a
pool of studies from which the ones in the
review are a selection. Our method lets the
funnel plot tell us how much bias there may
have been in this selection.
Just because more people die of heart
disease than of lung cancer does not neces›
sarily mean that there are more deaths
attributable to passive smoking. A rather
similar review by He et al, who are looking at
studies of passive smoking and heart
disease, comes up with a relative risk of 1.28.3
Thus, in relative terms, the elevation of risk is
fairly similar.
In their letter, Hackshaw et al point out
that most of the range of estimates we
discuss is within their confidence band. Pub›
lication bias is another source of statistical
uncertainty but, unlike ordinary sampling
variability, acts in the downward direction
only. Whatever confidence range is given, it
tends to be just the single figure which is
remembered. If there is good reason to think
this is an overestimate, then surely this needs
to be pointed out.
Finally, Cates is right in pointing out that
we did not use logarithmic scales in our fun›
nel plot. We decided to plot the raw figures so
they could be compared more easily with the
various values of relative risk discussed in the
earlier article by Hackshaw et al. But this is
Letters
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just the presentation. Our analysis was in fact
based on log relative risks. To keep our paper
as simple as possible we omitted all such sta›
tistical technicalities. A complete description
of our method, including graphs on logarith›
mic scales, will appear later this year in the
new statistical journal Biostatistics.4
John Copas professor
Jain Qing Shi research fellow
University of Warwick, Coventry CV4 7AL
Competing interests: None declared.
1 Hackshaw AK, Law MR, Wald NJ. The accumulated
evidence on lung cancer and environmental tobacco
smoke. BMJ 1997;315:980›8.
2 Bero LA, Glantz SA, Rennie D. Publication bias and public
health policy on environmental tobacco smoke. JAMA
1994;272:133›6.
3 He J, Vupputuri S, Allen K, Prerost MR, Hughes J, Whelton
PK. Passive smoking and the risk of coronary heart
disease—a meta›analysis of epidemiologic studies. New
Engl J Med 1999;340:920›6.
4 Copas JB, Shi JQ. Meta›analysis, funnel plots and sensitivity
analysis. Biostatistics 2000 (in press).
Quality of randomised
controlled trials in head injury
Trials in head injury are more complex
than review suggests
Editor—The review by Dickinson and
colleagues1 shows a remarkably narrow view
of research in head injury and virtually
ignores the need to match the design to the
research question. Historically, many clinical
trials have been underpowered, but the
authors’ premise that the main aim of head
injury trials should be to detect changes of “a
few per cent” in the rate of death or disability
does not apply, for example, to phase I/II
trials in the acute stage nor the later interven›
tions used in many of their reviewed trials.
The authors might find it useful to reread the
article “Why do we need some large, simple
randomized trials?” by Yusuf et al (note the
word “some” in the title).2
Several factors influence the relevant
effect size and hence the size of the trial.
Some potentially powerful interventions in
severe head injury are not widely practicable
and are likely to be expensive, and therefore
evidence of a substantial effect is required if
budget holders are to be persuaded to
support them. The focus on a 10% benefit
has reflected a perception that funding
could be obtained for a treatment that
benefits 1 person in 10. However, even this
may be optimistic. Despite the 13% benefit
obtained from nimodipine treatment in sub›
arachnoid haemorrhage,3 corresponding to
a number needed to treat of eight, clinicians
have had difficulties in gaining funding for
the routine use of this drug. The effective›
ness in individual patients is also relevant.
Dickinson and colleagues say that
unfamiliarity among ethics committees and
investigators with the idea of randomisation
without consent obstructs recruitment. This
is erroneous and displays a dangerously
superficial attitude towards a complex area.
What urgently needs to be clarified is the
legal framework in which research in
incompetent adults takes place. Recent
legislation in the Scottish parliament con›
tained no provision for an exception to the
requirement to obtain informed consent.
Equally it is not clear that any legal
framework exists to allow research without
consent in the rest of the United Kingdom.
The authors highlighted inadequate
funding as one obstacle that has prevented
large randomised controlled trials of widely
practicable treatments for head injuries. The
corresponding author is an applicant to the
Medical Research Council for substantial
funding for developing the CRASH study4
into a full scale trial, a study that is in part
supported by the manufacturer of the agent
under trial. In view of this, and his
apparently strong position on this issue,5 it
may be found surprising that no competing
interests were declared.
Gordon D Murray professor of medical statistics
Department of Community Health Sciences,
Epidemiology and Statistics, University of
Edinburgh, Edinburgh EH8 9AG
Gordon.Murray@ed.ac.uk
Graham M Teasdale professor of neurosurgery
University Department of Neurosurgery, Institute
of Neurological Sciences, Southern General
Hospital, Glasgow G51 4TF
Competing interests: As director of a charitable
organisation, the European Brain Injury Consor›
tium, Professor Murray has been active in providing
statistical advice to several pharmaceutical compa›
nies on the design, conduct, and analysis of clinical
trials in head injury—namely, Bayer, Cambridge
Neuroscience, Novartis, Pharmos, SmithKline Bee›
cham, and Synthelabo. In addition to extensive
declared interests in head injury (BMJ
2000;230:1631›5), Professor Teasdale was a
co›applicant to the Medical Research Council and a
member of the steering committee for the pilot
phase of the CRASH study but is not an applicant
for funding for the full phase and has withdrawn
from the steering committee.
1 Dickinson K, Bunn F, Wentz R, Edwards P, Roberts I. Size
and quality of randomised controlled trials in head injury:
review of published studies. BMJ 2000;320:1308›11.
(13 May.)
2 Yusuf S, Collins R, Peto R. Why do we need some large,
simple randomized trials? Stat Med 1984;3:409›22.
3 Pickard JD, Murray GD, Illingworth R, Shaw MDM,
Teasdale GM, Foy PM, et al. Effect of oral nimodipine on
cerebral infarction and outcome after subarachnoid
haemorrhage: British aneurysm nimodipine trial. BMJ
1989; 298: 636›42.
4 Yates D, Roberts I. Corticosteroids in head injury. BMJ
2000; 321: 128›9.
5 Dearlove O, Garry RF, Wager L, Roberts I, Wahlbeck K,
Adams C, et al. Beyond conflict of interest. BMJ 1999; 318:
464.
Authors’ reply
Editor—We are pleased that Murray and
Teasdale agree that clinical trials in head
injury have been too small and that some
large simple randomised controlled trials
are needed. To date, there have been no such
studies in head injury.
We are grateful to Professors Murray and
Teasdale for identifying yet another obstacle
to conducting large trials in head injury, the
idea that to obtain funding a treatment must
benefit at least 1 person in 10. There is no
rational basis for the use of such a decision
rule. Many factors impact on the decision to
provide a treatment but considerations of
efficiency require that priority is given to
treatments that provide the greatest benefit
per unit of cost. Even expensive treatments
that benefit fewer than 1 person in 10 might
be worth funding if the intervention offers an
overall net welfare gain. In head injury, with
high rates of long term disability, such a
situation might easily occur.
When the effect size is large even small
trials may be able to detect it. However,
Murray and Teasdale fail to appreciate that
both the size and the precision of the
estimated treatment effect must be taken
into account in therapeutic decision making.
Large trials, with larger numbers of outcome
events, provide more precise estimates of
treatment effect, and the true treatment
effect is likely to be close to what has been
observed. Imprecise estimates of even large
treatment effects from poor quality trials
make clinical and funding decisions difficult.
We agree that the legal framework in
which research in incompetent adults takes
place needs to be clarified. Given that such
senior investigators as Murray and Teasdale
are unclear on this issue, we hope that we
might be forgiven for suggesting that less
experienced investigators also find this issue
problematic.
In our paper we openly and publicly
make the scientific argument for some large
simple randomised trials in head injury. We
openly and publicly acknowledge that the
same scientific argument underpins the
Medical Research Council’s CRASH trial
(corticosteroid randomisation after signifi›
cant head injury), the first large simple
randomised controlled trial in head injury.
Open scientific argument in the pages of a
medical journal does not constitute a
conflict of interest and we are surprised that
Murray and Teasdale think otherwise.
Finally, we would point out that the
CRASH trial is sponsored by the Medical
Research Council and not the manu›
facturers of the agent under trial. The
manufacturers have donated the drug for
the trial to the Medical Research Council,
but the design, management, and finance of
the trial are entirely independent of them.
Ian Roberts senior lecturer in epidemiology
Ian.Roberts@ich.ucl.ac.uk
Frances Bunn review group coordinator, Cochrane
Injuries Group
Reinhard Wentz information specialist, Cochrane
Injuries Group
Phil Edwards research fellow
Child Health Monitoring Unit, Institute of Child
Health, University College London, London
WC1N 1EH
Competing interests: None declared.
If in doubt, declare competing interests
Editor—Five years ago it was unusual for
contributors to medical journals to declare
competing interests even though they often
had them. Now, increasingly, contributors do
declare them, but there continues to be con›
fusion over when to declare.
The BMJ started its campaign on compet›
ing interests by asking authors to declare any
sort of competing interest, be it personal,
political, religious, or whatever. Now we
concentrate on financial competing interests
because they are easier to define and there is
stronger evidence that they matter.
Dr Roberts and others chose not to
declare that they had applied to the Medical
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Research Council for a grant for a large trial
of the treatment of head injury. The BMJ’s
guidance to contributors says: “A competing
interest exists when professional judgment
concerning a primary interest (such as
patients’ welfare or the validity of research)
may be influenced by a secondary interest
(such as financial gain or personal rivalry).”
It seems entirely plausible that the view of Dr
Roberts and others on the desirability of a
large trial of treatment of head injury may
be influenced by the Medical Research
Council’s being more likely to award them a
grant if that view becomes widely accepted.
In my judgment, they would thus have been
wiser to declare their competing interest.
There is nothing wrong with having
competing interests, and my advice to
contributors is: “If in doubt, declare.”
Richard Smith editor, BMJ
Use of steroids for acute spinal
cord injury must be reassessed
Editor—Yates and Roberts’s editorial on
corticosteroids in head injury caused me
considerable concern in so far as it
portrayed the situation for treating acute
spinal cord injury.1 Intravenous high dose
methylprednisolone given within eight
hours of injury has been promoted since the
second American national acute spinal cord
injury study. The positive benefit of this is
based on conclusions derived from a
selected post hoc subgroup analysis in one
clinical trial. Current recommendations
regarding evidence of clinical efficacy con›
sistently advise caution in applying results
from such non›randomised groups of
patients.2
The evidence produced by a systematic
review that colleagues and I recently carried
out did not support the use of high dose
methylprednisolone in acute spinal cord
injury to improve neurological recovery.3 We
also concluded that “a deleterious effect on
early mortality and morbidity cannot be
excluded by this evidence.” In terms of
experimental acute spinal cord injury, the
functional neurological results extracted
from non›rodent animal studies using high
doses of either methylprednisolone or
dexamethasone “constituted a body of
evidence which cannot endorse a beneficial
effect.” A trend to increased mortality in cat
models of high spinal cord lesions was of
concern. On the basis of information
available to them, clinicians in Canada4 and
the United States5 also consider it inappro›
priate to advise treatment with methylpred›
nisolone in this context.
An independent assessment of the
evidence available, particularly information
from the American national acute spinal
cord injury studies, is long overdue.
Deborah Short consultant in spinal cord injuries and
rehabilitation medicine
Midlands Centre for Spinal Injuries, Robert Jones
and Agnes Hunt Orthopaedic and District Hospital
NHS Trust, Oswestry SY10 7AG
debbie.short@rjahoh›tr.wmids.nhs.uk
1 Yates D, Roberts I. Corticosteroids in head injury. BMJ
2000;321:129›30. (15 July.)
2 Oxman AD, Guyatt GH. A consumer’s guide to subgroup
analyses. Ann Intern Med 1992;116:78›84.
3 Short DJ, El Masry WS, Jones PW. High dose methylpred›
nisolone in the management of acute spinal cord injury—a
systematic review from a clinical perspective. Spinal Cord
2000;38:273›86.
4 Hulbert RJ. Methylprednisolone for acute spinal cord
injury—an inappropriate standard of care. J Neurosurg
(Spine 1) 2000;93:1›7.
5 Coleman WP, Benzel D, Cahill DW, Ducker T, Geisler F,
Green B, et al. A critical appraisal of the reporting of the
national acute spinal cord injury studies (I and II) of meth›
ylprednisolone in acute spinal cord injury. J Spinal Disord
2000;13:185›99.
Out of hours demand is higher
in Wales than in England and
Scotland
Editor—Contact rates for out of hours
services are greater in Wales than in
England and Scotland. Statistics gathered by
two south Wales cooperatives based in
Gwent and Neath Port Talbot show that the
workload is considerably higher than that
indicated by Salisbury et al.1
The Gwent cooperative covers a popu›
lation of 116 040 patients and 56 doctors
and the Neath cooperative 95 000 patients
and 52 doctors. The number of patient
contacts/1000 patients/year in 1999 was
204 in Gwent and 346.5 in Neath. This
compares with the reported rates for those
English and Scottish cooperatives that
included bank holiday cover (both Welsh
organisations provide this) of 145 and 221.
The table compares the figures for the
Gwent and Neath cooperatives with those
for England and Scotland given by Salis›
bury et al. Although statistics have been col›
lected in different ways, reasonably accurate
comparisons can be made.
The Neath area does not attract high
deprivation payments; my practice of 6150
patients, which is typical of the area, receives
band 1 deprivation payments for 248
patients and band 2 deprivation payments
for 132 patients. The Neath cooperative is
19 years old and moved into a dedicated
treatment centre in 1996. Figures indicate
that demand has reached a plateau, the
number of calls having been between
32 000 and 33 000 for the past three years.
Considerable seasonal variation occurs,
with a much higher demand in December
and January. Figures for December 1999
and January 2000 were 4206 and 3750
respectively.
NHS Direct has yet to be introduced in
Wales. Colleagues who are aware of these
figures and who have had long experience in
dealing with high demand doubt whether
NHS Direct Wales will be able to cope with
such numbers. We are also worried that
recruitment of nurses from our already
overstretched hospitals to staff NHS Direct
will lead to a further deterioration in
secondary services.
All cooperatives and deputising services
should be encouraged to collect and collate
accurate statistics so that future decisions on
the provision of out of hours services are
evidence based.
Bryan John general practitioner
Health Centre, Briton Ferry, Neath, Wales
SA11 2SF
bryn@2oldroad.freeserve.co.uk
1 Salisbury C, Trivella M, Bruster S. Demand for and supply
of out of hours care from general practitioners in England
and Scotland: observational study based on routinely
collected data. BMJ 2000;320:618›21. (4 March.)
Treatment for intestinal
helminth infection
Contrary to authors’ comments,
meta›analysis supports global helminth
control initiatives
Editor—Dickson et al’s meta›analysis of the
effects of treatment for intestinal helminth
infection on growth and cognitive perform›
ance in children has produced two impor›
tant findings, only one of which has been
discussed by the authors.1
The meta›analysis has helped highlight
the poor quality of many of the trials carried
out so far. The more important result (not
remarked on) is the extraordinary finding
that, despite the many systematic differences
observed between the studies used in the
meta›analysis, treatment unfailingly has a
positive average effect on both the outcomes
studied (table 3). In addition, the fact that
many systematic differences were observed
between the studies in the meta›analysis seri›
ously questions the value of trying to derive
global summary results for any of the
comparisons on both statistical and biological
grounds.
The result of the meta›analysis supports
an important principle for judging causality
from the results of clinical trials—that if
different trials address related questions
Details of patient contacts with two cooperatives in Wales, 1999, compared with figures given in study
done in England and Scotland1 (statistics have been collected in slightly different ways). Figures for
England and Scotland are numbers (percentages); those for Gwent and Neath are percentages alone
England/Scotland Gwent Neath
Total No of patient contacts 899 657 23 726 33 097
Given advice 408 407 (45.4) 46 35.6
Given home visit 212 550 (23.6) 20.5 16.7
Asked to visit centre 267 663 (29.8) 19.3 40.1
Accessed telephone answering service Excluded by authors of study1 13.8 3.1
Admitted 30 743/554 179 (5.5) 8.9 9.1
Average No of patient contacts/doctor/year NA 423.7 636.5
NA=Not available.
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then differences are more likely to occur in
the size of any effects than in their direction.
When interpreted in this light it is clear that
the present results provide quite firm
support for the conclusions of the better
designed individual trials that anthelmintic
treatment may indeed significantly improve
child growth and cognitive function; this is
in direct contrast to the authors’ own
pessimistic conclusion. Thus rather than
undermining the global helminth control
initiatives promoted by the World Bank and
World Health Organization, the present
review has actually produced evidence in
their support.
E Michael senior research fellow
Wellcome Trust Centre for the Epidemiology of
Infectious Disease, Department of Zoology,
University of Oxford, Oxford OX1 3FY
edwin.michael@ceid.ox.ac.uk
1 Dickson R, Awasthi S, Williamson P, Demellweek C,
Garner P. Effects of treatment for intestinal helminth infec›
tion on growth and cognitive performance in children:
systematic review of randomised trials. BMJ 2000;320:
1697›1701. (24 June.)
Conclusions should have been based on
broader considerations
Editor—In their systematic review on the
effects of treatment for intestinal helminth
infections on growth and cognitive perform›
ance in children, Dickson et al note
numerous shortcomings in the design of
previous studies.1 The authors themselves,
however, conclude misleadingly that devel›
oping countries should not invest in mass
treatment of children against helminth
infections.
Firstly, no studies have apparently been
designed to disentangle the effects of
helminth infections on cognitive function
from the effects of other sicknesses. Using a
dynamic multivariate random effects frame›
work to explain Kenyan children’s cognitive
test scores, I found that an index of morbid›
ity was significantly associated with lower
scores but that hookworm egg count per
gram of stool was not a significant predictor
of cognitive scores.2 The data were not suffi›
ciently detailed to shed light on the hypoth›
esis that helminth infections may be
negatively associated with cognitive test
scores because they increase the duration
and intensity of sicknesses.
Secondly, some psychologists have sug›
gested that helminth infections may occa›
sionally be beneficial for cognitive function.3
This would seem counter intuitive, and is
perhaps a fallacy arising from a failure to
recognise the nature of epidemiological
data. It is, for example, well known that
nutrient intakes exhibit day to day variation.
At the other extreme, psychological tests
such as the Brazelton neonatal behavioural
assessment scale are subject to high within
subject variation that often renders them
useless unless babies have neurological
defects.4 The magnitude of within subject
variability in schoolchildren’s cognitive
scores is lower than that for scores on the
neonatal behavioural assessment scale, but
this factor should be incorporated when
trials for assessing the effects of anthelmintic
treatment on cognitive function are being
designed. For example, the children could
be tested several times before and after the
treatment.
Finally, parasitic infections probably
exacerbate iron deficiency anaemia in
children growing up in unhygienic environ›
ments; bioavailability of iron from cereal
based diets is low. Iron deficiency anaemia,
in turn, is associated with poor learning.2 5
Anthelmintic treatment in most studies has
been of short duration, and reinfection rates
are typically high. It would therefore seem
premature for Dickson et al to conclude
that mass anthelmintic treatment may not
be cost effective. Rather, cost benefit analysis
of extended anthelmintic treatment, includ›
ing the development of vaccines against
certain types of infection, merit closer
attention. It would be far sighted to
approach anthelmintic treatment from a
broad long term perspective in developing
countries.
Alok Bhargava professor of economics
University of Houston, Houston, TX 77204›5882,
USA
bhargava@uh.edu
1 Dickson R, Awasthi S, Williamson P, Demellweek C,
Garner P. Effects of treatment for intestinal helminth infec›
tion on growth and cognitive performance in children:
systematic review of randomised trials. BMJ 2000;320:
1697›1701. (24 June.)
2 Bhargava A. A dynamic model for the cognitive
development of Kenyan schoolchildren. J Ed Psychol
1998;90:162›6.
3 Watkins WE, Pollitt E. “Stupidity or worms?”: Do intestinal
worms impair mental performance? Psychol Bull
1997;121:171›91.
4 Bhargava A. Modelling the effects of maternal nutritional
status and socioeconomic variables on the anthropometric
and psychological indicators of Kenyan infants from age
0›6 months. Am J Phys Anthropol 2000;111:89›104.
5 Pollitt E. Iron deficiency and cognitive function. Ann Rev
Nutr 1993;13:521›37.
Studies of short term treatment cannot
assess long term benefits of regular
treatment
Editor—The Cochrane review of
anthelmintic trials chiefly shows that studies
of short term treatment cannot assess the
long term benefits of regular treatment.1
When the World Health Organization,
Unicef, Unesco, and the World Bank
included deworming as one component of
their efforts to focus resources on effective
school health (the “FRESH start” partner›
ship) they intended that infrequent but
regular treatment from an early age would
ensure that children avoided heavy infec›
tion throughout the vulnerable years of
growth and development. A review of trials
that have not evaluated such a strategy is
not an appropriate basis for policy recom›
mendations, especially since the review
omitted, for example, the benefits of
avoiding hookworm anaemia and Trichuris
colitis.
The remarkable cost effectiveness of
deworming derives not from some easily
measured and immediate clinical benefit
of a single intervention but from the
longer term preventive value of an annual
investment of less than 7p.
Don Bundy knowledge coordinator




Clinical Trial Service Unit, University of Oxford,
Oxford OX3 9DU
1 Dickson R, Awasthi S, Williamson P, Demellweek C,
Garner P. Effects of treatment for intestinal helminth infec›
tion on growth and cognitive performance in children:
systematic review of randomised trials. BMJ 2000;320:
1697›1701. (24 June.)
Message does not follow from systematic
review’s findings
Editor—The number of parasites per host
in persistent parasitic infections such as the
helminthiases is characteristically dispersed
in a frequency distribution that is extremely
skewed compared with Gaussian or even
Poisson distributions.1 From this follow a
couple of points that are relevant to a meta›
analysis such as that by Dickson et al.2
Firstly, heterogeneity in parasite burdens is
of special importance, exceeding that of age
and drug type, which the authors had
hoped to take into account but could not do
from the primary trials. Secondly, attempt›
ing to allow for this heterogeneity by gener›
ating a random effects model may be
inappropriate since this is done by intro›
ducing an error term with an assumption of
Gaussian distribution of the error.3
More generally—and this point is also
related to the extremely skewed and over›
dispersed worm distributions—achieving
end points of growth and cognitive develop›
ment in trials of the treatment of popula›
tions, even where the prevalence of infec›
tions is high, needs thinking about. The
difference between having no worms and
having a few worms is probably much less
clinically important than the difference
between having some worms and having
an enormous burden of worms (having an
enormous burden is always relatively rare).
This is like the difference between
carriage of Neisseria meningitidis (high
percentage of the population) and invasive
meningococcal disease (a few thousand
cases a year in the British Isles). Currently in
the United Kingdom we are vaccinating
about 15 million people to prevent 1500
cases of type C meningococcal disease and
150 deaths a year. But we shall not be assess›
ing our effectiveness by changes in the total
morbidity or mortality of the 15 million
population, which would be lost in the dilu›
tion, or by any measure such as numbers
needed to vaccinate to prevent a case of
meningococcal disease: we will count the
individuals with type C meningococcal
disease.
In a similar way the greatest effect of
anthelmintic treatment on growth and
development of children will be concen›
trated in those with the heaviest parasite
burdens. This effect occurred in one of
the trials reviewed4 and was considerable
when only intense, severely symptomatic
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trichuriasis was treated,5 in a study where
placebo control would have been unethical.
The systematic review is useful, but the
message in the “What this study adds” panel
that “There is little evidence to support the
use of routine anthelmintic treatment to
improve growth and cognitive performance
in children in developing countries” does
not follow from its findings.
Ed Cooper consultant paediatrician
Newham General Hospital, London E13 8SL
edcooper@compuserve.com
Dr Cooper is an author of one of the trials reviewed.
1 Anderson RM, May RM. Helminth infections of humans:
mathematical models, population dynamics and control.
Adv Parasitol 1985;24:1›101.
2 Dickson R, Awasthi S, Williamson P, Demellweek C,
Garner P. Effects of treatment for intestinal helminth infec›
tion on growth and cognitive performance in children:
systematic review of randomised trials. BMJ 2000;320:
1697›701. (24 June.)
3 Greenland S. Meta›analysis. In: Rothman K, Greenland S,
eds. Modern epidemiology. 2nd ed. Philadelphia: Lippincott›
Raven, 1998:643›73.
4 Simeon D, Callender J, Wong M, Grantham›McGregor S,
Ramdath DD. School performance, nutritional status and
trichuriasis in Jamaican schoolchildren. Acta Paediatr
1994;83:1188›93.
5 Callender JEM, Grantham›McGregor SM, Walker SP,
Cooper ES. Treatment effects in trichuris dysentery
syndrome. Acta Paediatr 1994;83:1182›7.
Review needed to take account of all
relevant evidence, not only effects on
growth and cognitive performance
Editor—Dickson et al’s paper reflects the
public health importance of helminth
infections, particularly in children, adoles›
cent girls, and women of childbearing age.1
We are concerned, however, that on the
basis of limited evidence the reviewers
“would be unwilling to recommend that
countries or regions invest in programmes
that routinely treat children with
anthelminthic drugs.” As the authors state
in their introduction, the World Health
Organization, Unicef, the World Bank, and
the World Food Programme together with
partners and collaborators have strongly
recommended such interventions, having
regard to a substantial body of supportive
evidence, for the past 25 years.
The impact of population based chemo›
therapy depends on many factors. Local
patterns of mixed nematode infections
transmitted in soil, and their clinical
consequences, show important variations.
Whereas hookworm may be associated
primarily with iron deficiency anaemia,
Ascaris lumbricoides may be associated
mainly with stunting of growth. Intensity of
transmission, nutritional intake, and retreat›
ment schedules are among other variables
of fundamental importance. Assessing the
impact of regular anthelmintic chemo›
therapy must be related to these multiple
effects. Only then can proper policy implica›
tions and recommendations be given to
countries or regions.
To support their conclusion the review›
ers needed to take account of all relevant
evidence, not only the effects on growth and
cognitive performance. They seem to have
failed in this crucial requirement. For
instance, whereas they refer to the work of
Stoltzfus et al,2 they exclude reference to the
main finding that, in an area where
hookworm infection predominated, “this
deworming program prevented 1260 cases
of moderate›to›severe anemia and 276 cases
of severe anemia in a population of 30 000
schoolchildren in 1 year.”3
Finally, two of the authors of this letter
(LA and MA) are cited in the paper as being
members of the advisory panel to the
authors. Including their names may give the
impression that they agreed with the
content of the paper; in fact, they were not
consulted before publication.
Lorenzo Savioli coordinator, strategy development and
monitoring for parasitic diseases and vector control
saviolil@who.int
Maria Neira director
Control, Prevention and Eradication, World Health
Organization, 1211 Geneva 27, Switzerland
Marco Albonico scientific coordinator
Ivo de Carneri Foundation, 10122 Torino, Italy
Michael J Beach epidemiologist
Epidemiology Branch, Division of Parasitic
Diseases, Centers for Disease Control and
Prevention, Atlanta, GA 30341›3724, USA
Hababu Mohammed Chwaya director
Ivo de Carneri Public Health Laboratory, PO Box
3773, Chake›Chake, Pemba Island, Zanzibar,
United Republic of Tanzania
David W T Crompton head
World Health Organization Collaborating Centre
for Soil›transmitted Helminthiases, University of
Glasgow, Institute of Biomedical and Life Sciences,
Glasgow G12 8QQ
John Dunne former director
Division of Drug Management and Policies, World
Health Organization, 1211 Geneva 27, Switzerland
John P Ehrenberg regional adviser on communicable
diseases
Pan American Health Organization, 525, 23rd
Street, N W, Washington, DC, 20037, USA
Theresa Gyorkos associate director
McGill University, Division of Clinical
Epidemiology, Montreal General Hospital,
Montreal, Quebec H3G 1A4, Canada
Jane Kvalsvig director
Child Development Programme, University of
Natal, Durban 4041, Natal, South Africa
Martin G Taylor professor of medical helminthology
Department of Infectious and Tropical Diseases,
London School of Hygiene and Tropical Medicine,
London WC1E 7HT
Carlo Urbani public health specialist vector›borne and
other parasitic diseases
WHO Representative’s Office, PO Box 52, Hanoi,
Vietnam 1000
Feng Zheng director
Institute of Parasitic Diseases, Chinese Academy of
Preventive Medicine, 207 Rui Jin Er Lu, Shanghai
200025, People’s Republic of China
1 Dickson R, Awasthi S, Williamson P, Demellweek C,
Garner P. Effects of treatment for intestinal helminth infec›
tions on growth and cognitive performance in children:
systematic review of randomised trials. BMJ 2000;320:
1697›701. (24 June.)
2 Stoltzfus RJ, Albonico M, Tielsch JM, Chwaya HM, Savioli
L. School›based deworming program yields small
improvement in growth of Zanzibar school children after
one year. J Nutr 1997;127:2187›93.
3 Stoltzfus RJ, Albonico M, Chwaya HM, Tielsch JM, Schulze
KJ, Savioli L. Effects of the Zanzibar school›based
deworming program on iron status of children. Am J Clin
Nutr 1998;68:179›86.
Authors’ reply
Editor—Michael points out that the weight
changes favour the intervention. But the
differences in weight gain between the
groups are often small. Michael is incorrect
in saying that the evidence presented
provides firm support that anthelmintic
treatment significantly improves cognitive
function. It is certainly not the case, as he
implies, that treated children invariably do
better in cognitive and academic tests than
control children. Control children taking
placebo have shown greater gains in some
tests than treated children, and in some
cases this difference has been significant. On
this topic, Bhargava seems to imply that the
failure to find an effect may be due to the
unreliability of the tests. But most tests used
have had adequate to good reliability.
Bundy and Peto comment that our
review does not evaluate infrequent but
regular treatment from an early age. We
sought trials that repeated treatments, and
this was defined in our protocol. But there
were few such trials, and the data were
limited. The current large cluster ran›
domised trial in Lucknow will help provide
some answers to the effectiveness of these
strategies.
Cooper notes that the random effects
estimate may be inaccurate because of the
skewed dispersion of worms in a population.
His argument suggests that the uncertainty
around effect estimates is increased. In our
protocol we sought to conduct subgroup
analyses by intensity of worm burden, but no
trials provided the data necessary for us to
do this.
The letter from the World Health
Organization with 13 authors states that
they disagree with how we interpreted the
data, but again they do not provide substan›
tive evidence to support their past and
current recommendations. Savioli and
Albonico provided helpful input to the pro›
tocol development for this review. We did
not intend to imply that they had agreed
with the results of the review, only to
acknowledge their valuable input in the
review process; we will make this explicit in
the Cochrane review.
Several authors comment on the fact
that the review was not able to draw conclu›
sions about the effects of long term
treatments. We were unable to find any ran›
domised controlled trials that evaluated
long term benefit, and the evidence of short
term benefit was not, for us, convincing. We
therefore stand by our conclusion that it was
premature to recommend this widely, and
for countries to borrow money from the
World Bank to routinely implement national
population based policies of routine
repeated treatment. We believe that the
introductory statement to a World Health
Organization publication—that “regular
chemotherapy of infected populations
reduces mortality and morbidity in pre›
school children, improves nutritional status
and school performance of school
children”—is not based on current available
evidence.1
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Routine treatment with anthelminths
could well be an exciting and important
intervention. But we need the results of
larger, well designed trials, such as the
current trial in India, before lending money
to already poor countries to invest in an
intervention where there are doubts about
its wholesale benefit.
Paul Garner senior lecturer
Liverpool School of Tropical Medicine, Liverpool
L3 5QA
Rumona Dickson lecturer, school of health sciences
rdickson@liv.ac.uk
Colin Demellweek lecturer, department of clinical
psychology
Paula Williamson lecturer, department of
mathematical sciences
University of Liverpool, Liverpool L69 3GB
Shally Awasthi associate professor of paediatrics
King George Medical College, Lucknow, India
1 World Health Organization. Report of the WHO informal
consultation on the use of chemotherapy for the control of
morbidity due to soil transmitted nematodes in humans. Geneva:
WHO, 1996.
Adjuvant irradiation for breast
cancer
Treatment plans need to be made with
better anatomical information
Editor—Kunkler’s editorial on adjuvant
irradiation for breast cancer addressed an
important problem.1 More and more
patients of all age groups with potentially
highly curable disease are being treated with
both adjuvant chemotherapy and radiation.
It is therefore most important that the treat›
ment should be given in the safest possible
manner while maintaining its therapeutic
advantage. Increasingly, people recognise
that radiotherapy can improve survival in
breast cancer, and practitioners are becom›
ing aware not just of the cardiac morbidity
that occurs but also of the cardiac mortality.
To investigate the magnitude of these
problems we have undertaken a series of
magnetic resonance scans on patients before
radiotherapy planning and treatment. The
advent of magnetic resonance imaging has
allowed us to quantify the accuracy with
which radiotherapy treatments are being
delivered in breast cancer. The architecture of
our magnetic resonance scanner is open and
allows patients to be scanned in the treatment
position. Magnetic resonance images have
the advantage over other imaging techniques
in that they clearly show tumour, tumour bed,
and lymph nodes.
Because of the limited resource, patients
were chosen if they were to have radio›
therapy on the left side or if they were to
have extensive radiotherapy, including of
the nodes, to the right side. We have now
scanned 600 patients; preliminary analysis
on the first 200 clearly shows that, in at least
30% of cases, conventionally planned treat›
ments would have been suboptimal. As far
as the heart is concerned, more than 80% of
the left sided treatments would have
irradiated a considerable fraction of cardiac
tissue, quite often in the territory of the left
anterior descending coronary artery.
A finding of potentially greater
importance was that the tumour bed was
frequently missed. In the first 200 patients
more than 30% would have had complete or
partial treatment failure. In over 90% of the
patients requiring adjacent nodal irradiation
the entire cervicoaxillary chain below the
clavicle failed to be encompassed.
Despite the lack of precision of conven›
tional treatment planning that we have
shown, radiotherapy does improve survival.
It is therefore reasonable to expect that if
future treatment plans were made with the
benefit of adequate anatomical information,
its efficacy would be greatly enhanced. In
addition, cardiac morbidity and mortality
would be reduced.
Elisabeth Whipp consultant clinical oncologist
liz.whipp@ubht.swest.nhs.uk
Charles Candish specialist grade registrar
Bristol Oncology Centre, Bristol BS2 8ED
We thank the Friends of the Bristol Oncology
Centre for providing the open magnetic resonance
scanner and the medical physics department for
facilitating distortion correction and incorporating
the scans into the planning system.
1 Kunkler I. Adjuvant irradiation for breast cancer. BMJ
2000;321:1485›6. (3 June.)
Author’s reply
Editor—Whipp and Candlish provide per›
tinent data on the extent of cardiac
irradiation in patients with left sided
tumours or undergoing extensive adjuvant
locoregional radiotherapy. Their observa›
tions strongly support the case for more
sophisticated imaging during the planning
of breast radiotherapy than is available in
most centres in the United Kingdom. As
they point out, accuracy in treatment
delivery is important; two large randomised
trials showed a 9›10% survival advantage
from the addition of locoregional radio›
therapy to systemic treatment in high risk
women.1 2
The recent update of the Oxford
overview of randomised trials of breast
radiotherapy identified an increase in risk of
death from vascular causes (death rate ratio
1.30 (SE 0.09)).3 The overview does not pro›
vide any subgroup analysis of vascular
causes of death (for example, heart or great
vessels) by volume of irradiation of these
structures or laterality of tumour. An
analysis of vascular mortality by laterality is
planned in the next overview. Much less
information is available on cardiac morbid›
ity; this is not included in the overview.
Long term follow up of patients
included in the Danish Breast Cooperative
Group’s trials of postmastectomy irradiation
in high risk women receiving adjuvant
systemic treatment suggests that there is no
difference in cardiac morbidity or mortality
between irradiated and non›irradiated
groups.4 In these trials, electrons with limited
penetration beyond the chest wall would
have minimised dosage to the heart and
great vessels.
Most centres in the United Kingdom,
however, use a different treatment tech›
nique from that adopted in the Danish
trials. Using electronic portal imaging of
patients during adjuvant irradiation with
tangential megavoltage beams for left sided
breast tumours, Magee et al in Manchester
showed that the cardiac apex was irradiated
in 9% of cases.5 Cardiac morbidity and
mortality therefore need to be assessed in
long term prospective studies of adjuvant
locoregional irradiation.
At present, open magnetic resonance
facilities are not available in most depart›
ments. Currently, wide aperture (90 cm) com›
puted tomography simulators, adequate to
accommodate patients in the treatment posi›
tion adopted in many radiotherapy depart›
ments, are not commercially available.
An urgent dialogue is needed between
clinical oncologists to decide whether, to
minimise cardiac exposure, computed
tomography should be adopted for all
women undergoing irradiation for left sided
tumours. Until long term data on cardiac
morbidity and mortality from prospective
studies are available the avoidance of unnec›
essary cardiac irradiation seems a sensible
approach. The development of computed
tomography simulators with wider aper›
tures than are currently available is an
important priority.
Ian Kunkler consultant in clinical oncology
University Department of Clinical Oncology,
Western General Hospital, Lothian University
Hospitals NHS Trust, Edinburgh EH4 2XU
I.Kunkler@ed.ac.uk
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Comparing survival rates
between different registries can
be difficult
Editor—The paper by Stotter et al is an
important reminder of the need for caution
when comparing incidence and survival
rates between different populations.1 At the
Thames Cancer Registry we have developed
a method of estimating completeness of
ascertainment as a function of time since
diagnosis.2 As part of this procedure,
Kaplan›Meier estimates of survival are
calculated, and we have included cases regis›
tered solely on the basis of information from
their death certificates, assuming that their
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survival will be the same as that of cases in
whom the initial registration was made from
the death certificate but subsequent tracing
of records has led to further information
and a “proper” date of diagnosis.
Using data on all registered cancer cases
with a date of diagnosis (or date of death for
those cases registered on the basis of death
certificates only) in 1992, and calculating
survival with and without inclusion of these
cases by the above method, gives an
estimate of five year survival rate of 37%
when the cases registered on the basis of
their death certificate only are omitted and
30% when they are included (figure). This is
in line with the findings of Berrino et al,3
who showed that the percentage reduction
in estimated survival resulting from the
inclusion of such cases is generally of the
same order as the proportion of such cases
in the sample. The rate of cases registered
on the basis of their death certificate only
in the Thames Cancer Registry in 1992
was 19%.
A large rate of cases in whom the initial
registration was made from the death
certificate but additional information used
to gain further information and the date of
diagnosis—which implies that many cases
become known to the registry only when
they die—tends to bias survival estimates
downwards, as it leads to less complete
registration in young patients and those with
cancers associated with good long term sur›
vival. This effect can be seen when
comparing completeness estimates in
patients with lung cancer (94% complete
two years after diagnosis) and melanoma
(64%).2
It is important to know the rates of types
of registrations when comparing survival
rates between different registries.
David Robinson consultant statistician
dave.robinson@kcl.ac.uk
Janine Bell senior researcher
Henrik Młller director of research
Thames Cancer Registry, King’s College London
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Royal Medical Benevolent
Fund’s Christmas appeal
Editor—The Christmas season is almost
upon us and everyone, regardless of race or
creed, looks forward to one of the happiest
times of the year—but for some this is not so.
Those of us connected with the Royal Medi›
cal Benevolent Fund know very well the sad›
ness that follows unexpected tragedy within
our profession. The hardship that may
follow seems magnified at this time of year
and is all the more poignant when young
children are affected.
The generosity of BMJ readers last
Christmas helped the fund to distribute an
additional £75 000 to doctors less fortunate
than themselves, particularly their bereaved
families. Each year general grants from the
fund total well over £800 000.
The fund always seeks to give extra help
at Christmas with gifts for the children con›
cerned. May I therefore ask for your support
again this Christmas?
The Royal Medical Benevolent Fund is
very much your fund, which is why I am tak›
ing this opportunity to write to all doctors. I
hope that this Christmas you will decide to
contribute to our appeal. Our ability to help
depends on your generosity. I thank those
who are already members and all the other
doctors who have helped during the year,
and I particularly thank those who support
us for the first time this Christmas.
Contributions marked Christmas appeal
may be sent to the chief executive officer of
the fund at this address or to the treasurer of
your local guild of the fund. Thank you.
Rodney Sweetnam president
Royal Medical Benevolent Fund, 24 King’s Road,
London SW19 8QN
Support for studies in
paediatric medicine is needed
Editor—The paper by Aynsley›Green et al
highlighted the apparent lack of political
clout among those delivering medical
services for children.1 We have experienced
the effect of this in our efforts to pilot the use
of morphine›6›glucuronide as a sedative in
newborn babies who were given artificial
ventilation.
We wish to highlight the difficulties we
had in researching this drug, to give a better
understanding of why 90% of babies in neo›
natal units continue to receive unlicensed or
off›label drugs.2
Opiates are used frequently in neonatal
medicine, and morphine is the most widely
used. Studies have examined their metabo›
lism and pharmacokinetics, but the knowl›
edge about pharmacodynamics is limited.
We studied the effects on respiratory drive in
14 babies being given ventilation who were
treated with standard doses of morphine.3
This showed a reduction in respiratory rate,
which was delayed by up to 12 hours and did
not occur until measurable amounts of
morphine›6›glucuronide were found in the
plasma. We proposed that morphine›6›
glucuronide may provide a more reliable
and faster acting means of sedation.
We approached a small pharmaceutical
company, which was able to supply
morphine›6›glucuronide free of charge for
our proposed pilot study. We also shared the
protocol with a professor of paediatric phar›
macology, who believed that it was an
appropriate study to undertake.
The local research ethics committee
considered our application and consulted
external expert assessors, whose names were
provided by the Royal College of Paediatrics
and Child Health. Approval was given,
subject to clarification about non›negligent
indemnification. The drug company would
not apply for an exemption certificate for
clinical trials, although it was doing so for a
study including adults, but there was no
financial incentive to support our study. We
therefore considered an exemption certifi›
cate for doctors and dentists. The matter of
non›negligent indemnification went to the
hospital trust, and legal advice was sought
about the likely financial exposure the study
would entail.
Although we have a sound basis for our
study, supported by our own research, the
current literature, and external assessors, to
date we have not been able to proceed. In
addition to setting up such a study, there are
important issues regarding obtaining con›
sent from parents in today’s climate. These
seem like insurmountable hurdles. Without
a change in support for such studies, how
will we address the real problem of giving
unlicensed medicines to many children
under our care or proceeding with research
into new treatments?
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